It will be co-led by Patrizia Cavazzoni, director of the FDA's Centre for Drugs Evaluation and Research (CDER), and Centre for Biologics Evaluation and Research (CBER) director Peter Marks.

providing additional therapies for those who do become hospitalised is an important step in combating this pandemic," said Patrizia Cavazzoni, director of the FDA's Centre for Drug Evaluation and ...

The FDA published it three days later, on the 28th. The recalled products include 8-ounce packages of La Fiesta brand "Unseasoned Bread Crumbs (Pan Rayado)" and "Seasoned Bread Crumbs (Pan Rayado ...

For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...

A new opioid-free pain medication was approved by the U.S. Food and Drug Administration (FDA) on Thursday, marking a non-addictive alternative for patients. Journavx (suzetrigine), made by Vertex ...

The drug is for moderate to severe acute pain. The U.S. Food and Drug Administration (FDA) on Thursday approved a new type of prescription pain medication for adults to treat moderate to severe ...

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s approval ...

For the first time in two decades, the FDA has approved a new class of non-opioid pain medication, offering an alternative to addictive opioids for patients seeking pain relief. The drug ...

If you buy through a BGR link, we may earn an affiliate commission, helping support our expert product labs. For the first time in over two decades, the U.S. Food and Drug Administration (FDA) has ...

“Today’s approval is an important public health milestone in acute pain management,” Jacqueline Corrigan-Curay, the acting director of the FDA's Center for Drug Evaluation and ...